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Analysis of BRCA1/2 variants 
of unknown significance 
in the prospective Korean 
Hereditary Breast Cancer study
Joo Heung Kim1,15, Sunggyun Park2,15, Hyung Seok Park3*, Ji Soo Park4*, Seung‑Tae Lee5, 
Sung‑Won Kim6, Jong Won Lee7, Min Hyuk Lee8, Sue K. Park9,10, Woo‑Chul Noh11, 
Doo Ho Choi12, Wonshik Han13 & Sung Hoo Jung14
Genetic testing for BRCA1 and BRCA2 is crucial in diagnosing hereditary breast and ovarian cancer 
syndromes and has increased with the development of multigene panel tests. However, results 
classified as variants of uncertain significance (VUS) present challenges to clinicians in attempting to 
choose an appropriate management plans. We reviewed a total of 676 breast cancer patients included 
in the Korean Hereditary Breast Cancer (KOHBRA) study with a VUS on BRCA mutation tests between 
November 2007 and April 2013. These results were compared to the ClinVar database. We calculated 
the incidence and odds ratios for these variants using the Korean Reference Genome Database. A total 
of 58 and 91 distinct VUS in BRCA1 and BRCA2 were identified in the KOHBRA study (comprising 278 
and 453 patients, respectively). A total of 27 variants in the KOHBRA study were not registered in the 
Single Nucleotide Polymorphism database. Among BRCA1 VUSs, 20 were reclassified as benign or 
likely benign, four were reclassified as pathogenic or likely pathogenic, and eight remained as VUSs 
according to the ClinVar database. Of the BRCA2 VUSs, 25 were reclassified as benign or likely benign, 
two were reclassified as pathogenic or likely pathogenic, and 33 remained as VUS according to the 
ClinVar database. There were 12 variants with conflicting interpretations of pathogenicity for BRCA1 
and 18 for BRCA2. Among them, p.Leu1780Pro showed a particularly high odds ratio. Six pathogenic 
variants and one conflicting variant identified using ClinVar could be reclassified as pathogenic 
variants in this study. Using updated ClinVar information and calculating odds ratios can be helpful 
when reclassifying VUSs in BRCA1/2.
Hereditary breast and ovarian cancer syndrome (HBOC) has been shown to be associated with germline muta-
tions in BRCA1 and BRCA21, spurring demands for genetic testing to identify pathogenic variations in these 
 genes2. The identification of a pathogenic BRCA mutation in a patient diagnosed with breast cancer not only 
affects their treatment and prognosis, but also enables the prevention of other  cancers3. Guidelines for the 
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management of pathogenic variants in BRCA1 and BRCA2 recommend consideration of risk-reducing medica-
tions or  surgeries4,5.
A genetic test for BRCA has four possible results: no mutation detected, pathogenic mutation, benign muta-
tion, or variant of uncertain significance (VUS). A VUS is an alteration in the gene sequence that has an unknown 
effect on the function of the gene product. This leaves patients and their physicians with uncertainty due to the 
inability to interpret the result in a clinical context and a lack of specific guidelines regarding genetic counseling 
or prophylactic management in mutation carriers and their  relatives6.
While an overall VUS rate of 7–15% in women who have received BRCA testing has been  reported7, the fre-
quency of VUS varies worldwide depending on the testing prevalence and population  ancestry7,8. Researchers 
reported a frequency of VUS of 21% in African-Americans, 5–6% in people of European ancestry in the United 
States, and 15% in European  laboratories9,10. Myriad Genetic Inc. (Salt Lake City, UT, USA) reported that they 
decreased the proportion of VUSs to 2.1% using accumulated  data11. However, these databases are not public 
or accessible.
In this study, we aimed to explore the prevalence of VUS in the Korean population and to reclassify these 
variants using the ClinVar database and the Korean Reference Genome Database (KRGDB).
Results
Baseline characteristics. Among 2,403 breast cancer patients in the Korean Hereditary Breast Cancer 
(KOHBRA) study, more than a quarter, 676 (28.13%) patients, had mutations that were classified as VUS. Simul-
taneous mutations of BRCA1 and BRCA2 were observed in 55 (55/676, 8.14%) patients. Of the 676 subjects, 278 
had a VUS in BRCA1, and 453 patients had a VUS in BRCA2 (Fig. 1). refSNP (RS) numbers were reviewed for 
262 and 440 subjects with BRCA1 and BRCA2 mutations, respectively.
Reclassification using public databases. Table  1 shows the reclassification results for VUS accord-
ing to the ClinVar database. We classified the results into four groups: benign/likely benign, VUS, conflicting 
interpretations of pathogenicity, and pathogenic/likely pathogenic. Benign/likely benign was the most common 
reclassification for both BRCA1 and BRCA2 VUSs. Table 2 shows the rank of VUS genes based on the number 
of patients.
Of the 278 patients with a BRCA1 VUS, 58 VUSs were identified, and 44 had RS numbers. Twenty of these 
variants, found in 193 patients, were classified as benign/likely benign. The least common VUSs were classified 
as pathogenic/likely pathogenic and comprised four variants in six patients (Table 1).
Of the 453 patients with BRCA2 VUSs, 91 VUSs were identified, and 78 had RS numbers. The most common 
VUSs were benign/likely benign, comprising 25 variants in 328 patients. Meanwhile, pathogenic/likely patho-
genic variants were the least common and included two variants in three patients.
Figure 1.  Schematic diagram of patient selection: BRCA1 and BRCA 2 (n = 55).
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Calculating minor allele frequency and plotting graphs thereof, we noted that minor allele frequen-
cies for all variants, except for BRCA1 c.4987-92A>G(rs8176233), BRCA1 c.3113A>G(rs16941), BRCA1 
c.3548A>G(rs16942), and BRCA2 c.2971A>G(rs1799944), had P values of 0.05 or less: all four of the variants 
lacking statistical significance were classified as benign (Supplementary Fig. S1).
In this study, six gene mutations previously classified as VUS were reclassified as likely pathogenic based on 
ClinVar review. The variants were BRCA1 c.5089T>C (p.Cys1697Arg), BRCA1 c.5509T>C (p. Trp1837Arg), 
BRCA1 c.5516T>C (p.Leu1839Ser), BRCA1 c.81-9C>G, BRCA2 c.8023A>G (p.Ile2675Val), and BRCA2 
c.9004G>A (p.Glu3002Lys).
Odds ratio estimation. We calculated the odds ratios (ORs) for each variant using the KRGDB, as shown 
in Fig. 2. The OR of BRCA1 c.5339T>C (p.Leu1780Pro) was significantly high in analysis with the Wald method 
with 95% confidence intervals (CI). The corresponding P value was 0.0127 before and 0.889 after Bonferroni 
correction.
Table 1.  Reclassification of patients diagnosed with variants of uncertain significance based on ClinVar data.
BRCA1 58 mutations (n = 278)
Benign/ likely benign 20 mutations (n = 193)
VUS 8 mutations (n = 8)
Conflicting in interpretations of pathogenicity 12 mutations (n = 55)
Pathogenic/ likely pathogenic 4 mutations (n = 6)
Variants not registered in SNP database 14 mutations (n = 16)
BRCA2 91 mutations (n = 453)
Benign/ likely benign 25 mutations (n = 328)
VUS 33 mutations (n = 58)
Conflicting in interpretations of pathogenicity 18 mutations (n = 51)
Pathogenic/ likely pathogenic 2 mutations (n = 3)
Variants not registered in SNP database 13 mutations (n = 13)
Table 2.  Top 10 high-frequency mutations based on the number of patients.
BRCA1 RS_number ClinVar No. of patients OR CI
c.4883T>C rs4986854 Benign 57 0.8649 0.5865–1.2754
c.4484 + 14A>G rs80358022 Benign 41 0.5823 0.3845–0.8818
c.2566T>C rs80356892 Benign 40 0.3659 0.2491–0.5374
c.3113A>G rs16941 Benign 17 0.0079 0.0049–0.0128
c.154C>T rs80357084 Conflicting interpretations of pathogenicity 15 0.4646 0.2421–0.8914
c.5339T>C rs80357474 Conflicting interpretations of pathogenicity 12 8.5181 1.1192–64.8277
c.4729T>C rs80356909 Conflicting interpretations of pathogenicity 9 1.2874 0.4314–3.8417
c.3448C>T rs80357272 Benign 8 0.6349 0.2448–1.6464
c.3548A>G rs16942 Benign 8 0.0046 0.0025–0.0086
c.547 + 14delG rs273902771 Conflicting interpretations of pathogenicity 6
BRCA2 RS_number ClinVar No. of patients OR CI
c.10234A>G rs1801426 Benign 67 0.6443 0.4627–0.8972
c.8187G>T rs80359065 Benign 57 0.7962 0.5445–1.1643
c.9649-19G>A rs11571830 Benign 40 0.5462 0.3609–0.8266
c.5785A>G rs79538375 Benign 33 0.8118 0.4922–1.339
c.2971A>G rs1799944 Benign 29 0.0432 0.0299–0.0623
c.2350A>G rs11571653 Benign 28 0.4624 0.2868–0.7456
c.1744A>C rs80358457 Benign 24 0.7135 0.4046–1.2581
c.7052C>G rs80358932 Benign/likely benign 12 0.6115 0.2826–1.3231
c.6325G>A rs79456940 Conflicting interpretations of pathogenicity 10 0.6488 0.2754–1.5285
c.623T>G rs80358865 Uncertain significance 9 1.2867 0.4313–3.8389
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Discussion
We re-evaluated genetic results in patients with VUSs in BRCA1 and BRCA2 using the ClinVar database. Since 
genetic characteristics can vary by  ethnicity7,9,10, this study aimed to identify the prevalence of VUS in the 
Korean population and to re-classify the results of initial genetic tests. Although initial genetic testing results in 
the KOHBRA study revealed a VUS in 676 patients (278 patients for BRCA1 and 453 patients for BRCA2) out 
a total of 2,403 breast cancer patients (28.13%, 676/2,403), re-evaluation revealed a lower frequency of VUSs 
(8.03%, 193/2,403). About a third of the variants that were originally classified as VUS in the KOHBRA study 
were reclassified as benign/likely benign or pathogenic/likely pathogenic, accounting for two-thirds of all VUS 
patients (71.45%, 483/676). This result suggests that a re-classification approach using the ClinVar database can 
reduce the frequency of VUSs in the Korean population.
About two-thirds of the VUSs in the KOHBRA study were reclassified as benign or likely benign [193/278 
(69.42%) of BRCA1 patients, 328/453 (72.41%) of BRCA2 patients, and 471/676 (69.67%) of all patients]. A third 
Figure 2.  Odds ratios (ORs) using Korean population data from the Korean Reference Genome Database 
(KRGDB). Variants that could be identified in the KRGDB were classified according to the ClinVar database 
(vertical axis). Round dots indicate ORs, and the continuous line through each dot indicates a 95% confidence 
interval. Variants with orange, green, and blue dots indicate conflicting interpretations of pathogenicity, 
uncertain significance, and benign/likely benign variants according to the ClinVar database, respectively.
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of the mutation types classified as VUS in the KOHBRA study were downgraded to benign or likely benign 
(20/58 mutations in BRCA1 and 25/91 in BRCA2). These results were consistent with previous  studies1,12,13: So 
et al. reported that 30/75 (40%) of VUS patients were reclassified as benign or likely  benign14. In our study, six 
patients with BRCA1 VUS (four mutations) and three patients with BRCA2 VUS (two mutations) were reclas-
sified as pathogenic or likely pathogenic.
In this study, six mutations in nine patients were reclassified from VUSs to pathogenic or likely patho-
genic variants. BRCA1 c.5089T>C (p.Cys1697Arg), BRCA1 c.5509T>C (p. Trp1837Arg), BRCA1 c.5516T>C 
(p.Leu1839Ser), and BRCA1 c.81-9C>G were interpreted as likely pathogenic among variants in BRCA1. BRCA2 
c.8023A>G (p.Ile2675Val) and BRCA2 c.9004G>A (p.Glu3002Lys) were interpreted as pathogenic/likely patho-
genic among variants in BRCA2 based on the ClinVar database. Since all six mutations are supported by sufficient 
evidence in functional studies (PS3)15–17, have not been reported in a genomic database for the general Korean 
population (PM2), are classified as pathogenic in ClinVar (PP5), and are deleterious mutations (PP3) accord-
ing to an in silico  study18, they should be reclassified as likely pathogenic or pathogenic mutations. For patients 
with these mutations, additional genetic counseling and proper management, such as familial genetic testing, 
risk-reducing medications, or risk-reducing surgery, are needed for the prevention of cancer.
Interestingly, we identified several cases with conflicting interpretations of pathogenicity, for which reviewed 
the current status of available evidence in the literature (Table 3). In such instances, calculating ORs can help to 
reclassify them. The KRGDB, which is a large-scale, single-race database collected from 1,722 Koreans, is built 
for precision medicine research. We analyzed the KRGDB data using the Wald method to obtain ORs and 95% 
CIs for all VUS variants (Fig. 2). Several mutations (7 BRCA1 and 9 BRCA2 mutations) were evaluated. Most of 
them showed no significance. However, BRCA1 c.5339T>C (p.Leu1780Pro) showed possible pathogenicity, while 
BRCA1 c.154C>T (p.Leu52Phe) and BRCA2 c.964A>C (p.Lys322Gln) were potentially benign. However, with 
the most conservative multiple test correction, Bonferroni correction, the statistically significance of c.5339T>C 
disappeared. This non-significant level should be carefully interpreted, because several previous studies indi-
cated that this c.5339.T>C variant is pathogenic or likely pathogenic according to clinicopathologic features 
and American College of Medical Genetics (ACMG)  guidelines13,19–21. Therefore, even though the P value after 
multiple correction indicated a lack of statistical significance, c.5339T>C should be interpreted as a pathogenic 
or likely pathogenic variant in light of other functional evaluations, including co-segregation, in vitro, and in 
silico analyses. In verifying additional pathogenic mutation candidates, we merely referred to OR and CI values, 
but do not insist that OR values alone should be applied. With further accumulation of data in the future, we 
may be able to recalculate these ORs of P values. Meanwhile, variants BRCA 1 c.5014_5016delCAC, BRCA 1 
c.5332G>A, BRCA2 c.182T>C, BRCA 2 c.1909 + 22delT, BRCA 2 c.8486A>G, and BRCA2 c.8954-5A>G have 
not been reported in the general population and should remain classified as VUS, since there are no reports on 
their deleterious function.
Interpretations of VUSs are complex. Functional studies for reclassifying VUS could be a promising approach. 
Traditionally, VUS interpretation has depended on inductive conclusions based on information of individual 
 patients22. However, many potential variants in BRCA are present at low variant allele frequencies, with pheno-
types that are incompletely penetrant. Findlay et al. reported the application of saturation genome editing (SGE) 
to measure the functional outcomes of all possible single nucleotide variants (SNVs) in key areas of  BRCA115. 
Functional effects were almost concordant with the established assessments of pathogenicity. Function scores 
using SGE could help with interpreting the significance of VUSs by providing functional classification and 
assessment of ambiguous or newly-discovered variants.
The four BRCA1 mutations (c.5089T>C (p.Cys1697Arg), c.5509T>C (p.Trp1837Arg), c.5516T>C 
(p.Leu1839Ser), and c.81-9C>G) identified as likely pathogenic using the ClinVar database were identified as 
non-functional in Findlay’s  study15. The c.5339T>C (p.Leu1780Pro) variant identified as having conflicting inter-
pretations of pathogenicity in the ClinVar database was also identified as “non-functional” in the functional study 
results, suggesting this variant as  pathogenic15. On the other hand, other variants with conflicting interpretations 
of pathogenicity in the ClinVar database (including c.154C>T (p.Leu52Phe), c.5068A>C (p.Lys1690Gln), and 
c.5332G>A (p.Asp1778Asn)) have been categorized as functional or  intermediate15. The other BRCA1 variants 
with conflicting interpretations of pathogenicity in the ClinVar database could not be evaluated according to 
Findlay’s study, as it analyzed only RING and BRCT domains as  targets15.
Cosegregation analysis may also be helpful in re-evaluating VUSs. Zuntini et al. performed cosegregation 
analysis for 13 VUSs in 11 kindreds to improve VUS evaluation, and two variants were found to have additional 
supporting evidence of  pathogenicity23. Among the variants that were reclassified as pathogenic variants in our 
study, BRCA1 c.5509T>C (p. Trp1837Arg) was discussed in Zuntini’s study as well; however, due to the distinct 
nature of our data, cosegregation analysis could not be conducted. Cosegregation analysis may help improve 
understanding of VUSs and provide genetic counseling for specific families, sufficient for pedigree analysis.
When ORs were calculated using the KRGDB for all KOHBRA data, the OR of BRCA1 c.5339T>C 
(p.Leu1780Pro) was found to be significantly elevated (Fig. 2). This variant was also identified as non-functional 
in Findlay’s study. In addition, several studies have suggested that this mutation is pathogenic based on other 
evidence, including a strong family history of breast and ovarian cancer, absence in general population data, 
impaired function demonstrated by in silico studies, and triple negativity in clinicopathologic  features13,14,21. 
Previous studies have used a similar approach to reclassify some  variants24,25.
One limitation of the study is that we reviewed the VUSs by assigning them to a database based on a mostly 
Caucasian population. Researchers contributing to the Single Nucleotide Polymorphism (SNP) database or 
ClinVar tend to be concentrated in Western countries, leading to a lack of registration of major variants in Asian 
populations or a lack of interpretation of variants such as L1780P. Nevertheless, this study was meaningful in 
that it confirmed VUS status in Koreans using a prospective study and lays the groundwork for broadening our 
understanding of VUSs and conducting further research. Another limitation of the study is that there is missing 
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information in the KOHBRA data, which are necessary to reclassify VUSs (e.g., 27 variants were not submitted 
to the SNP database). However, the lacking data comprised only 4.29% of the cohort and would unlikely weaken 
the power of the current study.





significance (Likely) Benign No. of patients OR CI
c.1357G>C,
p.Glu453Gln rs768054411 3 1 1
c.154C>T
p.Leu52Phe rs80357084 5 3 15 0.4646 0.2421–0.8914
c.2481A>C
p.Glu827Asp rs397508970 2 1 1 0.7082 0.0446–11.2359
c.2726A>T
p.Asn909Ile rs80357127 8 1 2
c.4729T>C
p.Ser1577Pro rs80356909 1 7 9 1.2874 0.4314–3.8417
c.5014_5016delCAC 
p.His1673del rs80358343 3 4 1
c.5068A>C
p.Lys1690Gln rs397507239 8 1 1 0.2358 0.0246–2.2601
c.5332G>A
p.Asp1778Asn rs80357112 2 3 1
c.5339T>C
p.Leu1780Pro rs80357474 4 1 12 8.5181 1.1192–64.8277
c.547 + 14delG
c.547 + 14delG rs273902771 2 4 6
c.671-8A>G
c.671-8A>G rs80358144 1 4 5 0.8852 0.2385–3.2849
c.811G>A





significance (Likely) Benign No. of patients OR CI
c.10150C>T
p.Arg3384Ter rs397507568 1 5 2 0.4717 0.0791–2.8122
c.1568A>G
p.His523Arg rs80358443 2 9 2 0.2855 0.0554–1.4714
c.1817C>T
p.Pro606Leu rs80358469 5 1 1 0.7145 0.0448–11.4046
c.182T>C
p.Leu61Pro rs1555280374 2 1 1
c.1909 + 22delT rs276174816 1 7 1
c.317-10A>G rs81002824 1 1 1
c.3256A>G
p.Ile1086Val rs80358571 5 2 3
c.4599A>C
p.Lys1533Asn rs80358694 3 5 1
c.5554G>A
p.Val1852Ile rs80358777 4 2 1 0.7078 0.0446–11.225
c.5969A>C
p.Asp1990Ala rs148618542 6 1 7 1.2391 0.3642–4.216
c.6101G>A
p.Arg2034His rs80358849 2 1 1
c.6131G>T
p.Gly2044Val rs56191579 1 8 4 0.4078 0.1194–1.3933
c.6325G>A
p.Val2109Ile rs79456940 2 10 10 0.6488 0.2754–1.5285
c.7522G>A
p.Gly2508Ser rs80358978 7 6 9 0.5353 0.2254–1.2713
c.8092G>A
p.Ala2698Thr rs80359052 6 4 1
c.8486A>G
p.Gln2829Arg rs80359100 2 1 1
c.8954-5A>G rs886040949 5 1 1
c.964A>C
p.Lys322Gln rs11571640 3 9 4 0.2375 0.0766–0.7367
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Taken together, most of the mutations that were classified as VUS in the KOHBRA study were reclassified as 
benign. Four VUSs in BRCA1 and two in BRCA2 VUS were reclassified as pathogenic or likely pathogenic. When 
ORs were calculated using the KRGDB for all KOHBRA data, the OR of BRCA1 c.5339T>C (p.Leu1780Pro) 
was significantly high, although ClinVar considered BRCA1 c.5339T>C to have conflicting interpretations of 
pathogenicity. These seven mutations could be reclassified as likely pathogenic or pathogenic mutations, accord-
ing to ACMG guidelines. Since the mutations classified as benign in ClinVar have a high normal frequency, it 
is desirable to judge them as benign.
However, some VUSs remained as having conflicting interpretations of pathogenicity, rather than being re-
assessed as benign or pathogenic. Their characteristics will likely be more discernable with the accumulation 
of more information. When a VUS is reclassified as pathogenic/likely pathogenic, appropriate management, 
including risk-reducing medication and surgery, should be discussed with patients and their families. In addition 
to collecting individual data, functional studies using genetic techniques, such as SGE, could help contribute to 
the functional classification and assessment of VUSs.
Methods
Subjects. The study population was obtained from the Korean Hereditary Breast Cancer (KOHBRA)  study26. 
The KOHBRA study is a multicenter prospective cohort study designed to investigate the prevalence and causes 
of hereditary breast cancer in the Korean population. Through the study, 3,015 subjects were recruited between 
May 2007 and December 2013 from 36  institutions27. The eligibility criteria were as follows: (1) breast cancer 
patients with a family history of breast or ovarian cancer; (2) breast cancer patients without a family history of 
breast or ovarian cancer (non-familial) who were aged 40 years or younger at diagnosis and were diagnosed with 
bilateral breast cancer or another primary malignancy; (3) male breast cancer patients; and (4) family members 
of BRCA 1/2 mutation carriers. After excluding several subjects, a total of 2953 subjects (1228 familial breast 
cancer patients, 1175 non-familial breast cancer patients, and 550 family members of affected carriers) were 
evaluated. We identified 676 breast cancer patients with VUS on BRCA mutation tests.
These results were reclassified using the ClinVar database (http:// www. ncbi. nlm. nih. gov/ clinv ar/) based on 
refSNP (RS) numbers. Odds ratios (ORs) for each variant were calculated using Korean population data from the 
KRGDB, which was established by conducting whole genome sequencing of 1,722  Koreans28. Variants that were 
not registered in the Single Nucleotide Polymorphism (SNP) database are shown in Table 1. In this study, varia-
tions without RS numbers were also included in the denominator when checking the overall frequency of VUS.
BRCA 1/2 mutation analysis. BRCA 1/2 genetic testing was performed using genomic DNA from the 
peripheral blood. Of the 2403 patients, clinicians used fluorescence confirmation sensitive capillary (gel) electro-
phoresis on 1183 patients, direct sequencing on 1101 patients, and denaturing high-performance liquid chroma-
tography on 119  patients27. Each testing method was selected according to the laboratory linked to the institu-
tion. All BRCA 1/2 mutations were classified as pathogenic, VUS, or polymorphic.
Statistical analysis. Chi-square or Fisher’s exact tests were used for categorical variables. ORs and 95% 
confidence intervals were obtained using the Wald method. We retrieved allele frequencies from 1722 Koreans 
(KRGDB). For each variant, an OR was calculated based on its occurrence in 2403 patient cases and in the 
KRGDB. All analyses were performed using SPSS version 23 (SPSS; Chicago, IL, USA), and statistical signifi-
cance was defined as P < 0.05.
Mutation nomenclature. All sequence variations are described according to the HUGO-approved sys-
tematic nomenclature (http:// www. hgvs. org/ mutno men/) using GenBank reference sequences (NM_007294.2 
for BRCA 1 and NM_000059.3 for BRCA 2). The breast cancer information core nomenclature is also presented 
for convenience.
This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University. (IRB# 
4-2017-0255).
Data availability
The genotype and clinical phenotype data that support the findings of this study are not publicly available due to 
ethical and patient consent constraints. However, genotype and basic clinical phenotype data are available upon 
reasonable request from the corresponding author [H.S.P.] under a collaboration and data usage agreement.
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